Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOHEMIA: Ivermectin MDA for Malaria Reduction
NCT04966702Phase 3Completed
- Sponsor
- Barcelona Institute for Global Health
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ivermectin in malaria (3 arms), sponsored by Barcelona Institute for Global Health. Primary endpoints: Incidence of clinical malaria at 6 months and Safety of ivermectin MDA at 6 months. Started Mar 2022; status: completed.
02
Drugs
ivermectin
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04966702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966702.